Ordina (AMS:ORDI) Signs Contract With Postkantoren BV For IT Service Delivery
Ordina (AMS:ORDI) Nieuwegein, the Netherlands, 18 November 2008
Companies in the News
European Finance News
Pöyry Oyj (HEL:POY1V) ESA IKÄHEIMONEN APPOINTED CHIEF FINANCIAL OFFICER OF PÖYRY
Pöyry Oyj (HEL:POY1V) Pöyry PLC Company Announcement 18 November 2008 at 9.00 a.m.
Active Biotech (STO:ACTI) Teva Completes Enrollment In Laquinimod Phase III Clinical Trial
Active Biotech (STO:ACTI) - Recruitment Still Ongoing For Second, Pivotal Phase III Study, Bravo - Jerusalem, Israel and Lund, Sweden, November 18, 2008 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced completion of patient enrollment for the Phase III clinical trial, Allegro, in relapsing-remitting multiple sclerosis (RRMS). The pivotal Allegro study is designed to evaluate the efficacy, safety and tolerability of the oral investigational compound, laquinimod, versus placebo in the treatment of RRMS.
Marine Farms ASA (OSL:MAFA) 3rd Quarter 2008 Results
Marine Farms ASA (OSL:MAFA) In the third quarter 2008, Marine Farms obtained a net profits of NOK 27.8 mill compared to NOK 24.9 mill in the same period last year. Its salmon operations in the UK continue to do well, generating an EBIT/kg gwt sold salmon of NOK 7.4. Its seabass/seabream operations in Spain experienced a drop in profit, mainly due to historically low seabream prices as well as increased production costs. The group's financial position is solid. At the end of September 2008, equity amounted to NOK 490 mill (39.6% equity ratio). As pr 30.09.2008, the group had approximately NOK 270 mill in free cash and available credit facilities.
Nestlé S.A. (VTX:NESN) Lars Olofsson Leaves Nestlé
Nestlé S.A. (VTX:NESN) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
MorphoSys AG (FRA:MOR) MorphoSys And Wacker Intensify Cooperation To Use Wacker Technology for Production Of Antibodies
MorphoSys AG (FRA:MOR) MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and Wacker Chemie AG are intensifying their cooperation in the use of WACKER's prokaryotic secretion technology. The two companies have signed a new agreement precisely defining areas of use and production limits under which MorphoSys will continue to use the secretion system on a research scale. As a result, MorphoSys will now be able to use the WACKER technology for both the early development phase of therapeutic projects as well as the production of diagnostic and research antibodies. If the agreed quantity limits are exceeded at MorphoSys, WACKER is able to provide a seamless transition to large-scale manufacturing services.
Deep Sea Supply (OSL:DESSC) Mandatory Notification
Deep Sea Supply (OSL:DESSC) Hemen Holding Ltd has extended a TRS agreement that expired November 17, 2008. The TRS agreement has exposure to 3,100,000 underlying shares in Deep Sea Supply. New expiry date is February 17, 2009, and new TRS price is NOK 9.2353.
◂Previous Page
European Finance News Next Page▸
Banking & Finance
- NSX Limited (ASX:NSX) Company Update
- ASIC vs iSignthis Ltd and Nickolas John Karantzis
- NSX Limited (ASX:NSX) Appointment of Managing Director and CEO - Max Cunningham
Social Media
